Currently, there are three BRAF–MEK inhibition combination therapies approved for first-line treatment of metastatic melanoma with BRAF V600 activating mutations, including: Vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib [15]. The gene discussed is BRAF; the disease is metastatic melanoma.